as always this is all IMO
This company has a pretty good current ratio (almost 2x)...
On the most recent balance sheet I looked at it had 0 R&D and a jump of 5.5M in selling and admin expenses... mby popeye can clairify if this is an error or soemthing... but it looks strange to me...
Their revenues last quarter also went up significatly...
they ahve sold a friggin ton of stock over the past couple years... but last quarter they actually bought some back...
again anouther reasonably financially stable company, but its anouther one of those that could take a big hit if this big drug gets rejected... risk and reward |
Male
Logged
